利培酮治疗躁狂症对照观察

Controlled observation of risperidone in treatment of manic patients

目的:了解利培酮对躁狂症患者的疗效及不良反应。方法:对90例躁狂症患者随机分为单用利培酮组30例,利培酮合并碳酸锂组30例及氯氮平合并碳酸锂组30例,在治疗前及治疗第1、2、4、6、8周末分别评定Young氏躁狂量表(YMRS)、阳性与阴性症状量表(PANSS)及治疗中出现的症状量表(TESS),以了解疗效及不良反应。结果:单用利培酮组、利培酮合并碳酸锂组及氯氮平合并碳酸锂组治疗第2、4、6、8周末YMRS、PANSS总分均显著下降(P<0.01),但3组间比较差异无显著性(P>0.05)。治疗第4、6、8周末TESS总分3组间比较差异有显著性(P<0.01)。利培酮合并碳酸锂组及氯氮平合并碳酸锂组不良反应较单用利培酮组明显增多,尤其是氯氮平合并碳酸锂组更甚。结论:单用利培酮治疗躁狂症有效,而且不良反应更小。

Objective ： To observe the efficacy and side effects of risperidone in the treatment of manic patients. Method：Ninety manic patients were divided into three groups randomly, with 30 manic patients each. The first group was treated with risperidone, the second group were treated with risperidone combined with lithium carbonate,and the third group were treated with clozapine combined with lithium carbonate. The duration of treatment was 8 weeks. All the patients were assessed with Young＇ s mania rating scale （ YMRS）, the positive and negative syndrome scale（PANSS） and the treatment emergent symptoms scale（TESS） to measure to evaluate the therapeutic efficacy and side effects before and after 1,2,4,6,8 weeks treatment. Results：The total scores of PANSS and YMRS decreased significantly in three groups after treatments（P 〈 0.01 ）. No significant difference was found in the scores of PANSS and YMRS among three groups. There were significant differences in the scores of TESS among three groups at the end of 4th,6th,8th week after treatment（ P 〈 0.01 ） , and the side effects were more significantly in the second and third group than in the first group,especially more in the third group. Conclusion：Risperidone is effective in the treatment of mania,with less side effects.